Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

487 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sheddase activity of tumor necrosis factor-alpha converting enzyme is increased and prognostically valuable in head and neck cancer.
Ge L, Baskic D, Basse P, Vujanovic L, Unlu S, Yoneyama T, Vujanovic A, Han J, Bankovic D, Szczepanski MJ, Hunt JL, Herberman RB, Gollin SM, Ferris RL, Whiteside TL, Myers EN, Vujanovic NL. Ge L, et al. Among authors: ferris rl. Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2913-22. doi: 10.1158/1055-9965.EPI-08-0898. Epub 2009 Oct 20. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19843672 Free PMC article. Clinical Trial.
Phase I dendritic cell p53 peptide vaccine for head and neck cancer.
Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, Ferris RL. Schuler PJ, et al. Among authors: ferris rl. Clin Cancer Res. 2014 May 1;20(9):2433-44. doi: 10.1158/1078-0432.CCR-13-2617. Epub 2014 Feb 28. Clin Cancer Res. 2014. PMID: 24583792 Free PMC article. Clinical Trial.
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity.
Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, Horne W, Moskovitz JM, Kolls JK, Sander C, Shuai Y, Normolle DP, Kirkwood JM, Ferris RL, Delgoffe GM, Bruno TC, Workman CJ, Vignali DAA. Overacre-Delgoffe AE, et al. Among authors: ferris rl. Cell. 2017 Jun 1;169(6):1130-1141.e11. doi: 10.1016/j.cell.2017.05.005. Epub 2017 May 25. Cell. 2017. PMID: 28552348 Free PMC article.
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).
Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I. Ascierto PA, et al. J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. J Immunother Cancer. 2018. PMID: 29996914 Free PMC article. Review.
Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.
Tarhini A, Lin Y, Lin H, Rahman Z, Vallabhaneni P, Mendiratta P, Pingpank JF, Holtzman MP, Yusko EC, Rytlewski JA, Rao UNM, Ferris RL, Kirkwood JM. Tarhini A, et al. Among authors: ferris rl. J Immunother Cancer. 2018 Oct 23;6(1):112. doi: 10.1186/s40425-018-0428-5. J Immunother Cancer. 2018. PMID: 30352626 Free PMC article.
The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.
Ascierto PA, Butterfield LH, Demaria S, Ferris RL, Freeman GJ, Lo RS, Mantovani A, Nathan P, Hamid O, Politi K, Puzanov I. Ascierto PA, et al. Among authors: ferris rl. J Immunother Cancer. 2019 Aug 15;7(1):221. doi: 10.1186/s40425-019-0683-0. J Immunother Cancer. 2019. PMID: 31416487 Free PMC article. Review.
487 results